It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating the bone marrow (BM) of 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) after HSCT. A higher proportion of early-differentiated Memory Stem (TSCM) and Central Memory BM-T cells express multiple IR in relapsing patients than in CR patients. Exhausted BM-T cells at relapse display a restricted TCR repertoire, impaired effector functions and leukemia-reactive specificities. In 57 patients, early detection of severely exhausted (PD-1+Eomes+T-bet−) BM-TSCM predicts relapse. Accordingly, leukemia-specific T cells in patients prone to relapse display exhaustion markers, absent in patients maintaining long-term CR. These results highlight a wide, though reversible, immunological dysfunction in the BM of AML patients relapsing after HSCT and suggest new therapeutic opportunities for the disease.
Allogeneic hematopoietic cell transplantation is the standard treatment of acute myeloid leukemia, but many patients relapse. Here the authors show increased markers of exhaustion and cancer antigen specificity within bone marrow-residing memory T cells precede and potentially predict the relapse.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Griffioen Marieke 7 ; Halkes Constantijn J M 7 ; Falkenburg J H F 7 ; Stölzel Friedrich 8 ; Altmann, Heidi 8 ; Bornhäuser, Martin 8 ; Waterhouse, Miguel 9 ; Zeiser, Robert 9 ; Finke Jürgen 9 ; Cieri Nicoletta 10 ; Bondanza Attilio 5 ; Vago Luca 4 ; Ciceri Fabio 11 ; Bonini Chiara 12 1 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Experimental Hematology Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
2 IRCCS San Raffaele Scientific Institute, Hematology and Hematopoietic Stem Cell Transplantation Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
3 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Experimental Immunology Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
4 IRCCS San Raffaele Scientifc Institute, Division of Immunology, Transplantation and Infectious Disease, Unit of Immunogenetics, Leukemia Genomics and Immunobiology, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
5 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation and Infectious Diseases, Innovative Immunotherapies Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884)
6 Hokkaido University Faculty of Medicine, Graduate School of Medicine, Department of Hematology, Kita, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691)
7 Leiden University Medical Center (LUMC), Department of Hematology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
8 University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Department of Internal Medicine I, Dresden, Germany (GRID:grid.10419.3d)
9 University of Freiburg Medical Center, Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg, Germany (GRID:grid.7708.8) (ISNI:0000 0000 9428 7911)
10 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Experimental Hematology Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884); University of Milan, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
11 IRCCS San Raffaele Scientific Institute, Hematology and Hematopoietic Stem Cell Transplantation Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884); Università Vita-Salute San Raffaele, Milan, Italy (GRID:grid.15496.3f)
12 IRCCS San Raffaele Scientific Institute, Division of Immunology, Transplantation, and Infectious Diseases, Experimental Hematology Unit, Milan, Italy (GRID:grid.18887.3e) (ISNI:0000000417581884); Università Vita-Salute San Raffaele, Milan, Italy (GRID:grid.15496.3f)




